General Information of DTT (ID: TTJLNAW)

DTT Name Tissue kallikrein (KLK2) DTT Info
Gene Name KLK2

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
5 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Avoralstat DM5YHU2 Hereditary angioedema 4A00.14 Phase 2/3 [1]
VDA-1102 DMAJ85O Actinic keratosis EK90.0 Phase 2 [2]
JNJ-69086420 DM6VR13 Prostate cancer 2C82.0 Phase 1 [3]
JNJ-75229414 DMV6XBC Prostate cancer 2C82.0 Phase 1 [4]
JNJ-78278343 DM27FAN Prostate cancer 2C82.0 Phase 1 [5]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dermolastin DM6WSU2 Atopic dermatitis EA80 Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
DM-107 DMRYQVJ Atopic dermatitis EA80 Investigative [7]
hK2p01 derivative KLK2 inhibitor DME13RQ Discovery agent N.A. Investigative [8]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Vidac Pharma.
3 ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT05022849) A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
5 ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.
6 Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372).
8 Novel peptide inhibitors of human kallikrein 2. J Biol Chem. 2006 May 5;281(18):12555-60.